Irinotecan en es it fr

Irinotecan Brand names, Irinotecan Analogs

Irinotecan Brand Names Mixture

  • No information avaliable

Irinotecan Chemical_Formula


Irinotecan RX_link

Irinotecan fda sheet

Irinotecan FDA

Irinotecan msds (material safety sheet)

Irinotecan MSDS

Irinotecan Synthesis Reference

T. Miyasaka et al., U.S. pat. 4,604,463 (1985, 1986 both to Yakult Honsha)

Irinotecan Molecular Weight

586.678 g/mol

Irinotecan Melting Point

222-223 oC

Irinotecan H2O Solubility


Irinotecan State


Irinotecan LogP


Irinotecan Dosage Forms

Solution for IM injection

Irinotecan Indication

For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin).

Irinotecan Pharmacology

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of Irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either Irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks. The precise contribution of SN-38 to the activity of Irinotecan in humans is not known. Irinotecan is cell cycle phase-specific (S-phase).

Irinotecan Absorption


Irinotecan side effects and Toxicity

Gastrointestinal complications, such as nausea, vomiting, abdominal cramping, diarrhea, and infection.

Irinotecan Patient Information

Irinotecan Organisms Affected

Humans and other mammals